TX-PLANVIEW
22.6.2022 19:03:04 CEST | Business Wire | Press release
Planview ®, the global leader in Portfolio Management and Work Management, today announced the acquisition of Enrich , a product portfolio analytics company that empowers R&D organizations with complex portfolios to make strategic business decisions in real-time.
"As product portfolios continue to expand, companies are making big bets on business initiatives that can cost millions of dollars and take years to see to completion,” said Razat Gaurav, Chief Executive Officer at Planview. “Enrich brings deep expertise in complex product prioritization and data science techniques supporting portfolio decision-making, allowing companies to make more confident and insight-driven decisions on the investments that will achieve the greatest impact.”
“Enrich and Planview share a similar commitment: enabling our customers to achieve their most critical outcomes,” said Dr. Rich Sonnenblick, Founder and Chief Executive Officer at Enrich. “Over the last 24 years, we’ve worked with more than half of the leading life sciences companies globally to provide real-time visibility into the current and future health of their product pipelines, allowing them to make better investment decisions and align with business goals. We are looking forward to joining the Planview team and bringing our best-in-class simulation and analytics capabilities to Planview customers.”
Founded by Sonnenblick following his PhD from Carnegie Mellon University, Enrich provides a secure, cloud-based platform for portfolio prioritization, valuation, and scenario analysis using a tailored and flexible analytics engine seamlessly connected to a flexible visualization layer. The company’s emphasis is on establishing best-in-class, self-sufficient, strategic portfolio capabilities in every customer they work with.
Enrich’s Sonnenblick and his team of data scientists will join Planview, further deepening Planview’s data science and analytics expertise. Sonnenblick will serve as Planview’s Chief Data Scientist, focused on building and expanding the company’s data science initiatives and delivering predictive and prescriptive insights for Planview solutions.
Combining Enrich with Planview deepens the company’s commitment to product portfolio management and helping customers realize the future of connected work to accelerate the achievement of what matters most.
This acquisition closely follows the company’s announcement of its intent to acquire Tasktop , which is expected to close in Q3 of 2022.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com .
About Enrich Consulting
Founded in 1998, Enrich provides flexible analytics, scenario planning, simulation, and optimization techniques tailored for R&D teams to enable portfolio planning and prioritization, decision support, and risk analysis for highly-complex product portfolios. Leading Pharmaceutical and Life Sciences brands, including half of the top 20 life sciences companies, use Enrich to provide real-time visibility into the health of product portfolios, allowing them to make better decisions and align with business goals. For more information, visit: https://www.enrichconsulting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006173/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
